Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Zhou, P. et al. Nature 579, 270–273 (2020).
Korber, B. et al. Cell 182, 812–827 (2020).
Imai, Y. et al. Nature 436, 112–116 (2005).
Kuba, K. et al. Nat. Med. 11, 875–879 (2005).
Hofmann, H. et al. Biochem. Biophys. Res. Commun. 319, 1216–1221 (2004).
Monteil, V. et al. Cell 181, 905–913 (2020).
Wrapp, D. et al. Science 367, 1260–1263 (2020).
Yang, X. et al. J. Virol. 76, 4634–4642 (2002).
Fletcher, J. M. et al. ACS Synth. Biol. 1, 240–250 (2012).
Kirchdoerfer, R. N. et al. Sci. Rep. 8, 15701 (2018).
Chen, X., Zaro, J. L. & Shen, W. C. Adv. Drug Deliv. Rev. 65, 1357–1369 (2013).
Li, Q. et al. Cell 182, 1284–1294 (2020).
Yan, R. et al. Science 367, 1444–1448 (2020).
Zhou, T. et al. bioRxiv https://doi.org/10.1101/2020.07.04.187989 (2020).
Acknowledgements
We thank the Cryo-EM facility, Supercomputer Center of Westlake University. We thank the Core Facility of Microbiology and Parasitology (SHMC) and the Biosafety Level 3 Laboratory at Shanghai Medical College of Fudan University, especially Di Qu, Yutang Li, Qian Wang, Zhiping Sun and Chengjian Gu for continuous support. We thank Tian Li, Xingyue Bao, Mohamad Sawan, Dan Ma and Huaizong Shen for helping protein and cell preparations. We thank Peihui Wang for sharing ACE2 plasmid. This work was supported by Westlake Education Foundation and Tencent Foundation, the National Megaprojects of China for Major Infectious Diseases (2018ZX10301403 to L.L.), the Natural Science Foundation of China (22077104, 32022037, 31971123, 81920108015, and 31930059), the Key R&D Program of Zhejiang Province (2020C04001), and the SARS-CoV-2 emergency project of the Science and Technology Department of Zhejiang Province (2020C03129), and the Leading Innovative and Entrepreneur Team Introduction Program of Hangzhou.
Author information
Authors and Affiliations
Contributions
B.D. conceived the project. L.G., K.Z. and M.Z. performed the biochemical experiments, W.B., X.W., W.X, X.C., and Y.L. performed the viral experiments. R.Y., Y.Z. and Y.L. solved the cryo-EM structure. B.D., L.L., Q.Z., Y.X. and S.J. designed and supervised the experiments, interpreted the data, wrote and revised the manuscript.
Corresponding authors
Ethics declarations
Competing interests
B.D., L.G. and W.B. are the inventors on a provisional patent filed by the Westlake University. The other authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Guo, L., Bi, W., Wang, X. et al. Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection. Cell Res 31, 98–100 (2021). https://doi.org/10.1038/s41422-020-00438-w
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41422-020-00438-w
This article is cited by
-
Modulation of SARS-CoV-2 spike binding to ACE2 through conformational selection
Nature Nanotechnology (2025)
-
Computational design and engineering of self-assembling multivalent microproteins with therapeutic potential against SARS-CoV-2
Journal of Nanobiotechnology (2024)
-
Copper assisted sequence-specific chemical protein conjugation at a single backbone amide
Nature Communications (2023)
-
Polymerized porin as a novel delivery platform for coronavirus vaccine
Journal of Nanobiotechnology (2022)
-
A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein
Cell Discovery (2022)
